Health news
Radicava ORS® (edaravone oral suspension) is now available for the treatment of adults with amyotrophic lateral sclerosis (ALS). Radicava ORS contains the same active ingredient as Radicava, which was originally approved in 2017 as an…
The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of amyotrophic lateral sclerosis (ALS). The new Prescription Drug…
High-caloric interventions, including a high-caloric fatty supplement and a carbohydrate-rich high-caloric supplement, were able to induce weight gain in patients with amyotrophic lateral sclerosis (ALS). However, gastrointestinal (GI) symptoms and loss of appetite were the…
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is an oral, fixed-dose…
A phase 3 trial evaluating ravulizumab (Ultomiris) in adults with amyotrophic lateral sclerosis (ALS) has been discontinued. The multicenter, randomized, double-blind, placebo-controlled CHAMPION-ALS trial (ClinicalTrials.gov Identifier: NCT04248465) evaluated the efficacy and safety of ravulizumab, a…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021